Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Free Cash Flow: 2022-2025

Historic Free Cash Flow for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to -$28.1 million.

  • Entrada Therapeutics' Free Cash Flow fell 13.00% to -$28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$129.8 million, marking a year-over-year decrease of 643.23%. This contributed to the annual value of -$44.7 million for FY2024, which is 133.32% down from last year.
  • Per Entrada Therapeutics' latest filing, its Free Cash Flow stood at -$28.1 million for Q3 2025, which was up 5.45% from -$29.8 million recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' Free Cash Flow peaked at $201.7 million during Q1 2023, and registered a low of -$39.7 million during Q1 2025.
  • Over the past 3 years, Entrada Therapeutics' median Free Cash Flow value was -$26.4 million (recorded in 2024), while the average stood at -$734,818.
  • In the last 5 years, Entrada Therapeutics' Free Cash Flow surged by 1,034.59% in 2023 and then crashed by 546.22% in 2024.
  • Quarterly analysis of 4 years shows Entrada Therapeutics' Free Cash Flow stood at -$28.0 million in 2022, then surged by 82.19% to -$5.0 million in 2023, then slumped by 546.22% to -$32.2 million in 2024, then decreased by 13.00% to -$28.1 million in 2025.
  • Its Free Cash Flow was -$28.1 million in Q3 2025, compared to -$29.8 million in Q2 2025 and -$39.7 million in Q1 2025.